FDA — authorised 23 September 1997
- Application: NDA019922
- Marketing authorisation holder: HOSPIRA
- Local brand name: CORLOPAM
- Indication: INJECTABLE — INJECTION
- Status: approved
🇺🇸 Fenoldopam mesilate in United States
FDA authorised Fenoldopam mesilate on 23 September 1997 · 1 US adverse-event reports
Marketing authorisation
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 1
Most-reported reactions
- Drug Ineffective — 1 report (100%)
Other Cardiovascular approved in United States
Frequently asked questions
Is Fenoldopam mesilate approved in United States?
Yes. FDA authorised it on 23 September 1997.
Who is the marketing authorisation holder for Fenoldopam mesilate in United States?
HOSPIRA holds the US marketing authorisation.